G1 Therapeutics shares were up 9% to $2.85 in premarket trading after the company said it saw positive results from a Phase 2 trial for trilaciclib.
The company said it had 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with early-stage triple-negative breast cancer prior to receiving trilaciclib and neoadjuvant therapy.
G1 said these results show that trilaciclib has the potential to enhance long-term immune surveillance by increasing T cell function and generation of certain memory T cells and demonstrate gene expression profiles that may be associated with improved clinical outcome.
The data showed that trilaciclib has the greatest effect on longer term endpoints including overall survival, rather than earlier efficacy measures such as objective response rate and progression free survival, consistent with other immunotherapies like checkpoint inhibitors.